Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

eIF4E inhibitor

- PMLiVE

FDA turns down Pfizer’s Xeljanz in psoriasis

USregulator dampens the firm's hope of expanding arthritis drug's uses

- PMLiVE

FDA fast-tracks Merck/Pfizer’s rare skin cancer drug avelumab

Comes a month after drug was given orphan status

- PMLiVE

Pfizer launches first self-injectable contraceptive in UK

New option for female contraception hits UK

- PMLiVE

Study clears Pfizer’s Champix of serious risks

Smoking-cessation drug 'does not increase risk' of depression or heart attacks

- PMLiVE

India denies patent on Pfizer’s Xeljanz

Drug deemed not an invention because it is not more effective than original compound

- PMLiVE

Pfizer starts Ibrance trials in early breast cancer

Hopes to encourage wider use of breakthrough drug

- PMLiVE

Pfizer posts positive Trumenba vaccine data

Results from two new trials support FDA decision for accelerated approval

- PMLiVE

Pfizer and Flynn accused of overcharging for epilepsy drug

UK watchdog investigating the firms over the millions of pounds spent on Epanutin

- PMLiVE

Pfizer links with Synthon on generic Copaxone

US giant looking to grab a share of the copycat market for the MS drug

- PMLiVE

Pfizer takes MRSA vaccine into phase IIb trial

Trial will involve patients undergoing elective spinal fusion surgery

- PMLiVE

AstraZeneca’s Amie Baker wins Communiquétor 2015 award

And the UK pharma company takes home In-House team of the Year

Daiichi Sankyo logo

Daiichi Sankyo gets EU OK for Lixiana anticoagulant

Japanese firm’s latest product faces tough competition from a fierce NOAC market

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links